We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An FDA-funded study of Merck arthritis drug Vioxx found that the popular drug may increase the risk of serious heart problems, but the company disputed the report’s findings as inconsistent with results from clinical trials.
Canadians are paying hundreds of millions of dollars more for generic drugs each year than they would be in the absence of government policies that encourage inflated prices, according to a study by the Fraser Institute, a free market public policy organization based in Canada.
The U.S. Air Force no longer will dispense some widely used, but expensive, brand pharmaceutical products under new formulary guidelines that favor lower-cost brands and generic products.
The U.S. Pharmacopeia’s (USP’s) proposed guidelines for developing Medicare drug formularies could make it difficult for some brand products to make the cut, according to one pharmaceutical analyst.
One of the country’s largest pharmaceutical benefit managers has launched a new generic sampling initiative that offers coupons to waive the copayment for a generic drug treatment.
Generic firms reported mixed results in the quarter ending June 30, as generic competition and research and development (R&D) expenses cut into some companies’ bottom lines. Firms releasing financial statements recently included:
Ivax has launched the first generic version of Pfizer’s profitable epilepsy drug, Neurontin — a decision that could result in stiff financial penalties if a court later rules Ivax infringed on Pfizer’s patents.
The FDA has abandoned its own precedent that authorized generics are functionally and legally equivalent to true generics, Mylan Pharmaceuticals argues in a lawsuit that alleges the agency improperly allowed a brand-authorized generic to launch during Mylan’s generic marketing exclusivity period for the same drug.
Generic firms already battling each other for market share could face a new and growing competitor for their generic products — the brand firms themselves.